

Dear

## FREEDOM OF INFORMATION – CANCER PRESCRIBING

I write in response to your request for information in relation to cancer prescribing within NHS Lothian.

Question:

- How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with:

Answer:

1a	CAPOX ( <i>Capecitabine with Oxaliplatin</i> )	5<
1b	FOLFOX ( <i>Folinic acid, Fluorouracil and Oxaliplatin</i> )	Nil
1c	Lonsurf ( <i>Trifluridine - tipiracil</i> )	Nil
1d	Nivolumab in combination with Platinum ( <i>Cisplatin or Oxaliplatin</i> ) and Fluoropyrimidine ( <i>5-Fluorouracil or Capecitabine</i> )	6
1e	Pembrolizumab in combination with Platinum ( <i>Cisplatin or Oxaliplatin</i> ) and Fluoropyrimidine ( <i>5-Fluorouracil or Capecitabine</i> )	Nil
1f	Any other systemic anti-cancer therapy	53
1g	Palliative care only	NA

Question:

- How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

Answer:

2a	Atezolizumab ( <i>Tecentriq</i> )	5<
2b	Durvalumab ( <i>Imfinzi</i> )	8
2c	Nivolumab ( <i>Opdivo</i> )	Nil
2d	Pembrolizumab ( <i>Keytruda</i> )	Nil
2e	Chemotherapy	15
2f	Radiotherapy	NA
2g	Chemotherapy AND Radiotherapy	22

Question:

3. In the past three months, how many advanced renal cell carcinoma patients received the following first-line treatments:

Answer:

3a	Avelumab + Axitinib ( <i>Bavencio + Inlyta</i> )	Nil
3b	Cabozantinib ( <i>Cometriq</i> )	10
3c	Nivolumab ( <i>Opdivo</i> )	4
3d	Nivolumab + Cabozantinib ( <i>Opdivo + Cometriq</i> )	9
3e	Nivolumab + Ipilimumab ( <i>Opdivo + Yervoy</i> )	Nil
3f	Pembrolizumab + Lenvatinib ( <i>Keytruda + Kisplyx</i> )	5<

To protect the identity of the individuals involved any figure of 5 or less has not been shown in the table above. Since we do not have their consent to release this data from their records, the information is exempt under section 38(1)(b) of the Freedom of Information (Scotland) Act i.e. to provide it would breach the Data Protection Act (2018).

I hope the information provided helps with your request.

If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at [www.itspublicknowledge.info/Appeal](http://www.itspublicknowledge.info/Appeal). If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the FOI Reviewer at the email address at the head of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: <https://org.nhslothian.scot/FOI/Pages/default.aspx>

Yours sincerely

**ALISON MACDONALD**  
**Executive Director, Nursing, Midwifery and AHPs**  
 Cc: Chief Executive